Pantoprazol Tarbis Farma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Tarbis Farma, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Tarbis Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Tarbis Farma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosive lesions and prevents recurrence. - Peptic ulcer disease: supports ulcer healing and reduces risk of complications. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens (as adjunct): enhances ulcer healing when used with antibiotics.

Pantoprazol Tarbis Farma may cause adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation: occasional. - Dizziness: rarely reported.

Serious or Rare Side Effects: - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome, anaphylaxis). - Clostridioides difficile‑associated colitis. - Acute interstitial nephritis. - Low magnesium levels (hypomagnesemia) with prolonged use. - Fracture risk with long‑term high‑dose therapy. - Liver enzyme elevations indicating possible hepatic injury.

Before initiating therapy, consider the following precautions: - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring gastric acidity. - Evaluate for history of hypersensitivity to PPIs or related compounds. - Monitor long‑term users for magnesium levels and bone health. - Use the lowest effective dose for the shortest duration required. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several medicines. Awareness of these interactions helps maintain therapeutic efficacy.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir, nelfinavir): reduced absorption may compromise HIV treatment. - Certain antifungal agents (e.g., itraconazole, ketoconazole): decreased bioavailability.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: higher plasma concentrations reported; check levels if clinically indicated. - Clopidogrel: diminished antiplatelet effect; consider alternative antiplatelet therapy.